The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
The pathological process underlying Alzheimer’s disease in individuals under thirty
Abstract
Brains of 42 individuals between the ages of 4 and 29 were examined with antibodies (AT8, 4G8) and silver stains for the presence of intraneuronal and extracellular protein aggregates associated with Alzheimer's disease. Thirty-eight of 42 (38/42) cases displayed abnormally phosphorylated tau protein (pretangle material) in nerve cells or in portions of their cellular processes, and 41/42 individuals showed no extracellular amyloid-β protein deposition or neuritic plaques-an individual with Down syndrome was the only exception. In 16/42 cases abnormal tau was found in the transentorhinal region, and in 3/42 cases this site was Gallyas-positive for isolated NFTs (NFT stage I). Of 26 cases that lacked abnormal tau in the transentorhinal region, 4 did not show pretangle material at subcortical sites. The remaining 22 of these same 26 cases, however, had subcortical lesions confined to non-thalamic nuclei with diffuse projections to the cerebral cortex, and, remarkably, in 19/22 individuals the pretangle material was confined to the noradrenergic coeruleus/subcoeruleus complex. Assuming the pretangle alterations are not transient and do not regress, these findings may indicate that the Alzheimer's disease-related pathological process leading to neurofibrillary tangle formation does not begin in the cerebral cortex but, rather, in select subcortical nuclei, and it may start quite early, i.e., before puberty or in early young adulthood.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, it has been reported that NFTs are also very common in certain brainstem nuclei in subjects without dementia (39-44).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [39]
In the citing paper
“At 40 years, all individuals studied by Braak and Del Tredici (39) and Braak et al (44) exhibited at least initial neurofibrillary pathology in the brainstem (Fig. 5).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [39]
In the citing paper
“Neurofibrillary pathology is observed in the human brain long before Aβ plaques develop (39, 44, 300).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [39]
In the citing paper
“Although some studies have interpreted phosphorylated tau abnormalities in the locus coeruleus to be an early stage of AD pathology [15], young control subjects were not screened for a history of exposure to mTBI despite the fact that mTBI is common among young individuals and that 17 % of the control subjects died from acute trauma or accidental death.”
From The neuropathology of sport (2014) · cites this paper as [15]
In the citing paper
“The focal collections of perivascular NFTs in the depths of the cortical sulci in CTE [65, 66, 126–128] differ substantially from PHF-tau pathology of the Alzheimer type reported in some cognitively normal young adults [15], opiate abusers [4], and non-demented elderly subjects such as those in the Framingham Heart Study [6] or Honolulu Asian Aging Study [67, 194].”
From The neuropathology of sport (2014) · cites this paper as [15]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 7×
“Characteristic changes in the lesional distribution pattern are used to distinguish stages in the course of the process [1, 4, 13 , 18, 20, 51, 91].”
BackgroundMethodInfluentialSelf-citationThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Gauthier, S. G., Reisberg, ., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 4,096
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Self-citationBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citation
Research works printed but not linked: 1
- Braak H, Braak E, Yilmazer D, Schultz C, Bohl J (1995) Age-related changes of the human cerebral cortex. In: Cruz-Sanchez FF, Ravid R, Cuzner ML (eds) Neuropathologic diagnostic criteria for brain banking. IOS Press, Amsterdam, pp 14–19
Cited by
Sorted by citations
Items 201–300 of 813
Origins of Alzheimerʼs disease
Musiek, E. S., & Holtzman, D. M. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a30f4 · Cited by 85
Amyloid-β Increases Tau by Mediating Sirtuin 3 in Alzheimer’s Disease
Yin, J., Han, P., Song, M., Nielsen, M., Beach, T. G., Serrano, G. E., Liang, W. S., Caselli, R. J., & Shi, J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0977-0 · Cited by 83
Calderón‐Garcidueñas, L., Jewells, V. L., Galaz-Montoya, C. I., van Zundert, B., Pérez-Calatayud, Á. A., Ascencio-Ferrel, E., Valencia‐Salazar, G., Sandoval-Cano, M., Carlos, E., Solorio, E., et al. (2016) · Environmental Research · doi:10.1016/j.envres.2016.06.026 · Cited by 82
Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 84
The Role of Microglia in Sporadic Alzheimer’s Disease
Streit, W. J., Khoshbouei, H., & Bechmann, I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201248 · Cited by 87
Microvascular Alterations in Alzheimer's Disease
Steinman, J., Sun, H., & Feng, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.618986 · Cited by 85
Task-evoked pupil dilation and BOLD variance as indicators of locus coeruleus dysfunction
Elman, J. A., Panizzon, M. S., Hagler, D. J., Eyler, L. T., Granholm, E. L., Fennema‐Notestine, C., Lyons, M. J., McEvoy, L. K., Franz, C. E., Dale, A. M., et al. (2017) · Cortex · doi:10.1016/j.cortex.2017.09.025 · Cited by 82
Current directions in tau research: Highlights from Tau 2020
Sexton, C. E., Snyder, H. M., Beher, D., Boxer, A. L., Brannelly, P., Brion, J., Buée, L., Cacace, A. M., Chételat, G., Citron, M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12452 · Cited by 89
Chemosensory dysfunction in neurodegenerative diseases
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63855-7.00020-4 · Cited by 78
Eisele, Y. S., & Duyckaerts, C. J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1516-y · Cited by 82
Gomes, L. A., Uytterhoeven, V., Lopez-Sanmartin, D., Tomé, S. O., Tousseyn, T., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Verstreken, P., & Thal, D. R. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02251-6 · Cited by 77
Prokopiou, P. C., Engels, N., Papp, K. V., Scott, M. R., Schultz, A. P., Schneider, C., Farrell, M. E., Buckley, R. F., Quiroz, Y. T., Fakhri, G. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28986-2 · Cited by 81
Oxidative stress in Alzheimer's disease: Primary villain or physiological by-product?
Sutherland, G. T., Chami, B., Youssef, P., & Witting, P. K. (2013) · Redox Report · doi:10.1179/1351000213y.0000000052 · Cited by 80
Immunosenescence, inflammation and Alzheimer’s disease
Martorana, A., Bulati, M., Buffa, S., Pellicanò, M., Caruso, C., Candore, G., & Colonna‐Romano, G. (2012) · Longevity & Healthspan · doi:10.1186/2046-2395-1-8 · Cited by 76
Is sporadic Alzheimer′s disease a developmental disorder?
Arendt, T., Stieler, J., & Ueberham, U. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14036 · Cited by 76
Kovács, G. G., Horváth, M., Majtényi, K., Lutz, M. I., Hurd, Y. L., & Keller, É. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.07.018 · Cited by 75
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
Tian, J., Guo, L., Sui, S., Driskill, C., Phensy, A., Wang, Q., Gauba, E., Zigman, J. M., Swerdlow, R. H., Kroener, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6278 · Cited by 72
Hasegawa, M. (2016) · Biomolecules · doi:10.3390/biom6020024 · Cited by 75
Emerging β-amyloid pathology and accelerated cortical atrophy
Mattsson, N., Insel, P. S., Nosheny, R., Tosun, D., Trojanowski, J. Q., Shaw, L. M., Jack, C. R., Donohue, M. C., & Weiner, M. W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.446 · Cited by 71
Pu, D., Zhao, Y., Chen, J., Sun, Y., Lv, A., Zhu, S., Luo, C., Zhao, K., & Xiao, Q. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.04.017 · Cited by 71
The relationship between subcortical tau pathology and Alzheimer's disease
Attems, J., Thal, D. R., & Jellinger, K. A. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120034 · Cited by 72
Audouard, E., Houben, S., Masaracchia, C., Yilmaz, Z., Suain, V., Authelet, M., Decker, R. D., Buée, L., Boom, A., Leroy, K., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.06.008 · Cited by 73
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy
Walker, J. M., Richardson, T. E., Farrell, K. W., Iida, M. A., Foong, C., Shang, P., Attems, J., Ayalon, G., Beach, T. G., Bigio, E. H., et al. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa153 · Cited by 69
RNA Dynamics in Alzheimer’s Disease
Rybak‐Wolf, A., & Plass, M. (2021) · Molecules · doi:10.3390/molecules26175113 · Cited by 72
Ghosh, A., Torraville, S. E., Mukherjee, B., Walling, S. G., Martin, G. M., Harley, C. W., & Yuan, Q. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0511-2 · Cited by 74
The Molecular Pathology of Alzheimer's Disease
Harrington, C. R. (2012) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.003 · Cited by 70
Satoh, A., & Iijima, K. (2017) · Brain Research · doi:10.1016/j.brainres.2017.12.027 · Cited by 72
Tau pathology in children and young adults: can you still be unconditionally baptist?
Duyckaerts, C. J. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0794-7 · Cited by 77
Lloret, M.-A., Cervera-Ferri, A., Nepomuceno, M., Monllor, P., Esteve, D., & Lloret, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031168 · Cited by 68
Primate aging in the mammalian scheme: the puzzle of extreme variation in brain aging
Finch, C. E., & Austad, S. N. (2012) · AGE · doi:10.1007/s11357-011-9355-9 · Cited by 68
Pamphlett, R. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.11.016 · Cited by 70
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giovanni, G. D., Štrac, D. Š., Solé, M., Unzeta, M., Tipton, K. F., Mück‐Šeler, D., Bolea, I., Corte, L., Perković, M. N., Pivac, N., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00541 · Cited by 76
Canu, N., Amadoro, G., Triaca, V., Latina, V., Sposato, V., Corsetti, V., Severini, C., Ciotti, M. T., & Calissano, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061319 · Cited by 70
The Sleep Side of Aging and Alzheimer’s Disease
Romanella, S. M., Roe, D., Tatti, E., Cappon, D., Paciorek, R., Testani, E., Rossi, A., Rossi, S., & Santarnecchi, E. (2020) · Sleep Medicine · doi:10.1016/j.sleep.2020.05.029 · Cited by 72
Gilvesy, A., Husén, E., Maglóczky, Z., Mihály, O. S., Hortobágyi, T., Kanatani, S., Heinsen, H., Renier, N., Hökfelt, T. G. M., Mulder, J., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02477-6 · Cited by 77
FDG-PET and amyloid-PET imaging
Perani, D. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000109 · Cited by 69
Ashford, J. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150381 · Cited by 67
Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders
Hasegawa, M., Nonaka, T., & Masuda‐Suzukake, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.010 · Cited by 71
Dunn, M., Henke, A., Clark, S. D., Kovalyova, Y., Kempadoo, K. A., Karpowicz, R. J., Kandel, E. R., Sulzer, D., & Sameš, D. (2018) · Nature Communications · doi:10.1038/s41467-018-05075-x · Cited by 65
Osorio, R. S., Ducca, E. L., Wohlleber, M. E., Tanzi, E. B., Gumb, T., Twumasi, A., Tweardy, S., Lewis, C., Fischer, E., Koushyk, V., et al. (2016) · SLEEP · doi:10.5665/sleep.5846 · Cited by 65
Age-Related Neurodegeneration and Memory Loss in Down Syndrome
Lockrow, J. P., Fortress, A. M., & Granholm, A. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/463909 · Cited by 68
Interaction between -Synuclein and Other Proteins in Neurodegenerative Disorders
Jellinger, K. A. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/371893 · Cited by 64
Li, X., Lei, P., Tuo, Q., Ayton, S., Li, Q., Moon, S., Volitakis, I., Liu, R., Masters, C. L., Finkelstein, D. I., et al. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0378-2 · Cited by 63
Mastroeni, D., Delvaux, E., Nolz, J., Tan, Y., Grover, A., Oddo, S., & Coleman, P. D. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.017 · Cited by 63
Protein Tau: Prime Cause of Synaptic and Neuronal Degeneration in Alzheimer's Disease
Crespo‐Biel, N., Theunis, C., & LEUVEN, F. V. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/251426 · Cited by 69
Amyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo, A. A., & Lopera, F. J. (2016) · Colombia medica · doi:10.25100/cm.v47i4.2640 · Cited by 64
Encephalopathy induced by Alzheimer brain inoculation in a non-human primate
French Neuropathology Network, Gary, C., Lam, S., Hérard, A., Koch, J. E., Petit, F., Gipchtein, P., Sawiak, S. J., Caillierez, R., Eddarkaoui, S., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0771-x · Cited by 66
Correlations between cortical and subcortical tau pathology
Attems, J., Thomas, A. J., & Jellinger, K. A. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01244.x · Cited by 65
Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease
Egroo, M. V., Narbutas, J., Chylinski, D., González, P. V., Maquet, P., Salmon, É., Bastin, C., Collette, F., & Vandewalle, G. (2019) · SLEEP · doi:10.1093/sleep/zsz017 · Cited by 66
Dengler-Crish, C. M., Smith, M. A., & Wilson, G. N. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160658 · Cited by 61
Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation
Reilly, P., Winston, C. N., Baron, K. R., Trejo, M., Rockenstein, E. M., Akers, J. C., Kfoury, N., Diamond, M. I., Masliah, E., Rissman, R. A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.005 · Cited by 61
Ross, J. A., Gliebus, G. P., & Bockstaele, E. J. V. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.08.004 · Cited by 63
Developments in Tau PET Imaging
Zimmer, E. R., Leuzy, A., Gauthier, S., & Rosa-Neto, P. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2014.15 · Cited by 60
Ferrer, I., Andrés‐Benito, P., Ausín, K., Pamplona, R., del Río, J. A., Fernández‐Irigoyen, J., & Santamaría, E. (2021) · Brain Pathology · doi:10.1111/bpa.12996 · Cited by 61
Norepinephrine Protects against Amyloid-β Toxicity via TrkB
Liu, X., Ye, K., & Weinshenker, D. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141062 · Cited by 60
Roles and Mechanisms of Axon-Guidance Molecules in Alzheimer’s Disease
Zhang, L., Qi, Z., Li, J., Li, M., Du, X., Wang, S., Zhou, G., Xu, B., Liu, W., Xi, S., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02311-2 · Cited by 58
Szot, P., Franklin, A., Miguélez, C., Wang, Y., Vidaurrazaga, I., Ugedo, L., Sikkema, C. L., Wilkinson, C. W., & Raskind, M. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.09.003 · Cited by 59
Developing therapeutic vaccines against Alzheimer’s disease
Wısnıewskı, T., & Drummond, E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 60
Differences Between Human and Murine Tau at the N-terminal End
Hernández, F., Merchán‐Rubira, J., Vallés‐Saiz, L., Rodríguez-Matellán, A., & Ávila, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00011 · Cited by 64
Hu, W. H., Wu, F., Zhang, Y., Gong, C., Iqbal, K., & Liu, F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00311 · Cited by 63
The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype
Pletniková, O., Kageyama, Y., Rudow, G. L., LaClair, K. D., Albert, M., Crain, B. J., Tian, J., Fowler, D. R., & Troncoso, J. C. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.07.007 · Cited by 57
Alzheimer’s disease brain contains tau fractions with differential prion-like activities
Li, L., Shi, R., Gu, J., Tung, Y. C., Zhou, Y., Zhou, D., Wu, R., Chu, D., Jin, N., Deng, K., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01127-4 · Cited by 60
Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
Lim, N., Swanson, C. R., Cherng, H. R. R., Unger, T. L., Xie, S. X., Weintraub, D. A., MAREK, K. L., Stern, M. B., Siderowf, A. D., PARS Investigators, et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.299 · Cited by 57
Selective noradrenaline depletion impairs working memory and hippocampal neurogenesis
Coradazzi, M., Gulino, R., Fieramosca, F., Falzacappa, L. V., Riggi, M., & Leanza, G. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.012 · Cited by 56
Gannon, M. A., & Wang, Q. (2018) · Brain Research · doi:10.1016/j.brainres.2018.01.001 · Cited by 61
Geser, F., Prvulovic, D., O’Dwyer, L., Hardiman, O. M., Bede, P., Bokde, A. L. W., Trojanowski, J. Q., & Hampel, H. J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.011 · Cited by 58
Hypothesis review: Alzheimer's overture guidelines
Ferrer, I. (2022) · Brain Pathology · doi:10.1111/bpa.13122 · Cited by 56
Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00578-0 · Cited by 58
Spatiotemporal patterns of locus coeruleus integrity predict cortical tau and cognition
Bueichekú, E., Diez, I. P., Kim, C. M., Becker, J. A., Koops, E. A., Kwong, K. K., Papp, K. V., Salat, D. H., Bennett, D. A., Rentz, D. M., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00626-y · Cited by 70
Supporting evidence for using biomarkers in the diagnosis of MCI due to AD
Galluzzi, S., Geroldi, C., Amicucci, G., Bocchio‐Chiavetto, L., Bonetti, M., Bonvicini, C., Cotelli, M., Ghidoni, R., Paghera, B., Zanetti, O. O., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6694-0 · Cited by 55
Noradrenergic Hypothesis Linking Neurodegeneration-Based Cognitive Decline and Astroglia
Leanza, G., Gulino, R., & Zorec, R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00254 · Cited by 54
Li, Y., Xu, P., Shan, J., Sun, W., Ji, X., Chi, T., Liu, P., & Zou, L. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109618 · Cited by 52
Dammer, E. B., Shantaraman, A., Ping, L., Duong, D. M., Gerasimov, E. S., Ravindran, S. P., Guðmundsdóttir, V., Frick, E. A., Gómez, G., Walker, K. A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn3504 · Cited by 63
Strobel, S., Grünblatt, E., Riederer, P., Heinsen, H., Arzberger, T., Al‐Sarraj, S., Troakes, C., Ferrer, I., & Monoranu, C. M. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1369-5 · Cited by 55
Jiang, J., Wang, Z.-H., Qu, M., Gao, D., Liu, X.-P., Zhu, L., & Wang, J. (2015) · Scientific Reports · doi:10.1038/srep11765 · Cited by 57
Epidemiological Approaches to Understanding the Link Between Type 2 Diabetes and Dementia
Sutherland, G. T., Lim, J., Srikanth, V. K., & Bruce, D. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161194 · Cited by 58
Pamphlett, R., & Kum Jew, S. (2018) · BioMetals · doi:10.1007/s10534-018-0124-4 · Cited by 53
Kremen, W. S., Panizzon, M. S., Elman, J. A., Granholm, E. L., Andreassen, O. A., Dale, A. M., Gillespie, N. A., Gustavson, D. E., Logue, M. W., Lyons, M. J., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.001 · Cited by 50
Dugger, B. N., Hidalgo, J. A., Chiarolanza, G., Mariner, M., Henry-Watson, J., Sue, L. I., & Beach, T. G. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121864 · Cited by 53
Evolutional Aspects of Alzheimer's Disease Pathogenesis
Braak, H., & Tredici, K. D. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129029 · Cited by 54
Self-citationThickness network features for prognostic applications in dementia
Raamana, P. R., Weiner, M. W., Wang, L., & Beg, M. F. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.040 · Cited by 50
Early Improved and Late Defective Cognition Is Reflected by Dendritic Spines in Tau.P301L Mice
Kremer, A., Maurin, H., Demedts, D., Devijver, H., Borghgraef, P., & LEUVEN, F. V. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4859-11.2011 · Cited by 50
Ádori, C., Glück, L., Barde, S. S., Yoshitake, T., Kovács, G. G., Mulder, J., Maglóczky, Z., Havas, L., Bölcskei, K., Mitsios, N., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1394-3 · Cited by 53
Jacobs, H. I. L., Müller‐Ehrenberg, L., Priovoulos, N., & Roebroeck, A. F. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.05.021 · Cited by 51
Janitzky, K. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00371 · Cited by 56
Neuropathology of Parkinsonism in Patients with Pure Alzheimer's Disease
Horvath, J. E., Burkhard, P. R., Herrmann, F. R., Bouras, C., & Kövari, E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131289 · Cited by 48
The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
Yin, X., Qiu, Y., Zhao, C., Zhou, Z., Bao, J., & Qian, W. (2021) · Medical Science Monitor · doi:10.12659/msm.933084 · Cited by 48
The role of fatty acid amide hydrolase enzyme inhibitors in Alzheimer's disease
Jain, S., Bisht, A., Verma, K., Negi, S., Paliwal, S., & Sharma, S. K. (2021) · Cell Biochemistry and Function · doi:10.1002/cbf.3680 · Cited by 53
Calderón‐Garcidueñas, L., Mora-Tiscareño, A., Melo-Sánchez, G., Rodríguez-Díaz, J., Torres‐Jardón, R., Styner, M. A., Mukherjee, P. S., Lin, W., & Jewells, V. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150415 · Cited by 50
Neuroimaging biomarkers in Alzheimer’s disease and other dementias
Villemagne, V. L., & Chételat, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.004 · Cited by 55
Hickman, R. A., Flowers, X. E., & Wısnıewskı, T. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01063-1 · Cited by 48
Impaired astrocytic Ca2+ signaling in awake-behaving Alzheimer’s disease transgenic mice
Åbjørsbråten, K. S., Skaaraas, G. H. E. S., Cunen, C., Bjørnstad, D. M., Binder, K. M. G., Bojarskaite, L., Jensen, V., Nilsson, L. N. G., Rao, S. B., Tang, W., et al. (2022) · eLife · doi:10.7554/elife.75055 · Cited by 50
Calderón‐Garcidueñas, L., Stommel, E. W., Torres‐Jardón, R., Hernández-Luna, J., Aiello-Mora, M., González-Maciel, A., Reynoso-Robles, R., Pérez-Guillé, B., Silva-Pereyra, H. G., Tehuacanero-Cuapa, S., et al. (2024) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1297467 · Cited by 49
Opportunities and challenges in developing Alzheimer disease therapeutics
Iqbal, K., & Grundke, I. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0878-z · Cited by 48
Li, L., Cheung, T., Chen, J., & Herrup, K. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/171464 · Cited by 48
Pontifex, M. G., Vauzour, D., & Minihane, A. M. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.05.017 · Cited by 51
Counts, S., & Mufson, E. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374236-0.10012-4 · Cited by 44
ApoE4 inhibition of VMAT2 in the locus coeruleus exacerbates Tau pathology in Alzheimer’s disease
Kang, S. S., Ahn, E. H., Liu, X., Bryson, M., Miller, G. W., Weinshenker, D., & Ye, K. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02315-1 · Cited by 52
Engels, N., Koops, E. A., Prokopiou, P. C., Egroo, M. V., Schneider, C., Riphagen, J. M., Singhal, T., & Jacobs, H. I. L. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104998 · Cited by 45
Metadata
- Authors
- Braak, H., & Del Tredici, K.
- Affiliations
- Universität Ulm (DE)
- Corresponding author
- Braak, Heiko
- ORCID
- Braak, Heiko
- Venue
- Acta Neuropathologica
- Published
- 2010-12-15
- Volume
- 121
- Issue
- 2
- Pages
- 171-181
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2081533023
- Cited by
- 812
- References
- 103
- Citations by year
- 2026: 42 · 2025: 43 · 2024: 58 · 2023: 39 · 2022: 55 · 2021: 74 · 2020: 61 · 2019: 52 · 2018: 51 · 2017: 41 · 2016: 57 · 2015: 52 · 2014: 55 · 2013: 49 · 2012: 45
- FWCI
- 27.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, young adults, tau phosphorylation, neurofibrillary tangles, amyloid-beta, neuritic plaques, subcortical nuclei, AT8 antibody, Down syndrome
- MeSH terms
- Adolescent, Adult, Alzheimer Disease, Brain, Child, Child, Preschool, DNA-Binding Proteins, Female, Humans, Male, Neurons, Phosphorylation, Retrospective Studies, Cohort Studies, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Ubiquitin, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
